Atorvastatin differentially regulates the interactions of cocaine and amphetamine with dopamine transporters. (1st March 2023)

• Record Type: Journal Article
• Authors: Wang, Shiyu; Neel, Anna I.; Adams, Kristen L.; Sun, Haiguo; Jones, Sara R.; Howlett, Allyn C.; Chen, Rong
• Is Part Of: Neuropharmacology. Volume 225(2023)
• Publication Date: 2023-03-01
• Subjects: Dopamine transporter -- Cholesterol -- Atorvastatin -- Methyl-β-cyclodextrin -- Dopamine uptake -- Dopamine efflux; Neuropsychopharmacology -- Periodicals; Autonomic Agents -- Periodicals; Neuropsychopharmacologie -- Périodiques; Neuropsychopharmacology; Periodicals; Electronic journals; 615.78
• DOI: 10.1016/j.neuropharm.2022.109387
• Languages: English
• ISSNs: 0028-3908

Abstract

Abstract: The function of the dopamine transporter (DAT) is regulated by membrane cholesterol content. A direct, acute removal of membrane cholesterol by methyl-β-cyclodextrin (MβCD) has been shown to reduce dopamine (DA) uptake and release mediated by the DAT. This is of particular interest because a few widely prescribed statins that lower peripheral cholesterol levels are blood-brain barrier (BBB) penetrants, and therefore could alter DAT function through brain cholesterol modulation. The goal of this study was to investigate the effects of prolonged atorvastatin treatment (24 h) on DAT function in neuroblastoma 2A cells stably expressing DAT. We found that atorvastatin treatment effectively lowered membrane cholesterol content in a concentration-dependent manner. Moreover, atorvastatin treatment markedly reduced DA uptake and abolished cocaine inhibition of DA uptake, independent of surface DAT levels. These deficits induced by atorvastatin treatment were reversed by cholesterol replenishment. However, atorvastatin treatment did not change amphetamine (AMPH)-induced DA efflux. This is in contrast to a small but significant reduction in DA efflux induced by acute depletion of membrane cholesterol using MβCD. This discrepancy may involve differential changes in membrane lipid composition resulting from chronic and acute cholesterol depletion. Our data suggest that the outward-facing conformation of DAT, which favors the binding of DAT blockers such as cocaine, is more sensitive to atorvastatin-induced cholesterol depletion than the inward-facing conformation, which favors the binding of DAT substrates such as AMPH. Our study on statin-DAT interactions may have clinical implications in our understanding of neurological side effects associated with chronic use of BBB penetrant statins. Highlights: Both atorvastatin and MβCD reduce membrane cholesterol content. Both atorvastatin and MβCD reduce dopamine uptake and cocaine inhibition of dopamine uptake. Cholesterol replenishment prevents atorvastatin-induced reduction in dopamine uptake and cocaine inhibition. MβCD, but not atorvastatin, reduces amphetamine-induced, dopamine transporter-mediated dopamine efflux. The outward-facing conformation of DAT is more sensitive to atorvastatin treatment than the inward-facing conformation.